In the tumor microenvironment, a low fucosylated antibody against AMHR2, murlentamab (GM102), switches the pro-cancer nature of tumor-associated macrophages (TAMs) towards the anti-cancer action by activating immunological mechanisms leading to the destruction of tumor cells (186–189) (Figure 6). The gene discussed is AMHR2; the disease is neoplasm.